
Study Finds Wide Pay Gaps in Eye Care
The findings come from an analysis of January 2025 Transparency in Coverage data from four major insurers — Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Aetna — and highlight the inconsistent nature of pricing in eye care.
'Facility prices are negotiated by hospitals, health-system outpatient departments, and large ambulatory surgery centers that wield substantially more market clout than individual ophthalmologists,' said Alexander P. Philips of the Center for Advancing Health Policy Through Research at the Brown University School of Public Health in Providence, Rhode Island. 'Those institutions fold a wide range of fixed costs — real estate, equipment, around-the-clock staffing, and community-benefit obligations — into their rates, so the starting point for negotiation differs dramatically from one organization to the next.'
Philips and Christopher Whaley, PhD, also of the Center for Advancing Health Policy Through Research at Brown University School of Public Health, published their findings on July 3 in JAMA Ophthalmology .
For the analysis, Philips and Whaley looked at more than 740,000 price points for 10 high-volume ophthalmology procedures such as intravitreal injections, iris revision surgery, treatment for severe retinopathy, and laser surgery for postcataract treatment. They found facility fees paid by insurance companies often exceeded professional charges by factors of two to four.
For example, median facility prices for standard cataract surgery ranged from $1521 (Cigna) to $4274 (Aetna), a spread of $2753. In contrast, professional fees for the same procedure showed a much narrower interquartile spread of just $439, from $581 to $1020.
'What a physician can charge is anchored to well-known relative-value schedules that leave less room for maneuver,' Philips said. 'The moment a hospital acquires a previously independent office, the exact same cataract extraction can suddenly carry a separate facility component, widening the gap even further.'
For patients, the result can be unpredictable out-of-pocket costs that can skyrocket depending on where they undergo the procedure. 'Independent clinicians, meanwhile, find it harder to compete, and insurers ultimately load those higher facility payments into premiums,' Philips said.
Blue Cross Blue Shield consistently paid above-market rates, 14% higher for professional fees and 13% higher for facility fees, whereas Aetna showed the most dramatic divergence, with professional fees 54% below average and facility fees 45% above, the researchers found.
'Aetna appears to drive a hard bargain with individual physicians, who usually have limited leverage, while conceding more to large hospital systems that control valuable operating rooms and imaging equipment,' Philips told Medscape Medical News . 'That strategy allows the plan to advertise a lean physician fee schedule to employers, keeping the most visible line item in check, yet still maintain broad hospital networks by paying the premiums those systems demand on the facility side.'
'This pattern can look different across specialties; insurers often deploy distinct, specialty-specific tactics depending on whether hospitals, physician groups, or ancillary providers hold the upper hand,' he added. 'For example, UnitedHealth Group's deep vertical integration through Optum gives it the leverage to align professional and facility payments within its own physician and ambulatory-surgery platform, which produces a negotiation dynamic unlike what we see with Aetna in ophthalmology.'
Geographic Analysis
The study's geographic analysis revealed up to fivefold differences in median facility prices for cataract surgery across states. Outlier states like Connecticut and Alaska had significantly higher prices, potentially due to academic centers or Medicare payment policies, the researchers reported.
Philips and Whaley suggest market dynamics such as insurer-provider negotiations, selective contracting, and vertical integration play a major role in shaping these disparities. For instance, UnitedHealthcare's lower facility fees may reflect its ownership of care delivery assets through Optum, while Cigna's lower prices suggest a strategy of selective contracting with providers willing to accept lower reimbursement in exchange for volume.
The commentary also highlighted the potential of publicly available, insurer-posted data on negotiated prices to empower smaller practices. 'Transparent prices can empower smaller groups or solo practitioners with data for fair negotiations,' the authors wrote. 'Facility revenue can be indirectly critical for ophthalmologists in large departments.'
Still, both the study and commentary stress price alone is not a proxy for value. 'These prices are administrative constructs and may not reflect patient responsibility or the actual cost of care delivery,' the commentary noted.
'Patients should resist the reflex to equate a higher bill with better care. What matters far more is choosing the right setting: The same surgeon can perform a cataract extraction in a physician-owned ASC [ambulatory surgery center] for half of what it would cost in a hospital outpatient department, with no difference in clinical outcome,' Philips said. 'That said, both clinicians and patients have limited leverage to shift markets on their own; real progress depends on policy interventions that rein in unwarranted price dispersion across the system. Awareness helps individuals avoid the worst surprises, but meaningful change will flow from site-neutral payment reforms, tighter antitrust oversight, and transparency rules that expose and discourage outlier prices.'
Transparency Reforms
In an invited commentary, Sean T. Berkowitz, MD, MBA, of the Department of Ophthalmology at Vanderbilt University Medical Center in Nashville, Tennessee, and his coauthors from Cleveland Clinic, Cleveland, emphasized that ophthalmology is uniquely positioned to benefit from transparency reforms due to its high volume of standardized procedures.
However, they cautioned the data may not fully capture the nuances of care delivery. 'Site of service may impact findings,' they wrote. 'The proportion of hospital or ambulatory surgical centers in each network or geographic area may explain the larger variation in facility fees.'
They also warned that increased transparency could have unintended consequences. 'More data on local price variation may incentivize upward price pressure, consolidation, and vertical integration,' according to the authors of the commentary. 'Transparency must be paired with policies that promote competition and protect access.'
The authors of the paper and commentary reported no relevant financial conflicts of interest.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Despite lower earnings than a year ago, Five Below (NASDAQ:FIVE) investors are up 92% since then
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio). To wit, the Five Below, Inc. (NASDAQ:FIVE) share price is 92% higher than it was a year ago, much better than the market return of around 18% (not including dividends) in the same period. That's a solid performance by our standards! In contrast, the longer term returns are negative, since the share price is 3.9% lower than it was three years ago. Although Five Below has shed US$303m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the last year, Five Below actually saw its earnings per share drop 10%. Given the share price gain, we doubt the market is measuring progress with EPS. Indeed, when EPS is declining but the share price is up, it often means the market is considering other factors. We think that the revenue growth of 11% could have some investors interested. Many businesses do go through a phase where they have to forgo some profits to drive business development, and sometimes its for the best. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. So it makes a lot of sense to check out what analysts think Five Below will earn in the future (free profit forecasts). A Different Perspective It's nice to see that Five Below shareholders have received a total shareholder return of 92% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 5% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Five Below has 1 warning sign we think you should be aware of. But note: Five Below may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
BOK Financial Second Quarter 2025 Earnings: Beats Expectations
BOK Financial (NASDAQ:BOKF) Second Quarter 2025 Results Key Financial Results Revenue: US$535.3m (down 2.3% from 2Q 2024). Net income: US$138.5m (down 15% from 2Q 2024). Profit margin: 26% (down from 30% in 2Q 2024). The decrease in margin was primarily driven by higher expenses. EPS: US$2.19 (down from US$2.54 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period BOK Financial Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Looking ahead, revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Banks industry in the US. Performance of the American Banks industry. The company's shares are down 6.4% from a week ago. Balance Sheet Analysis Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of BOK Financial's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 登入存取你的投資組合
Yahoo
26 minutes ago
- Yahoo
Cruise line stocks are on the rebound this year. Here's why.
Cruise line stocks have been on a tear in recent months, with no signs of a slowdown as industry efforts to woo vacationers to the sea show signs of paying off. Carnival (CCL) shares have rebounded more than 60% from their April lows when tariff turmoil rocked the markets. Norwegian Cruise Line (NCLH) also rose 50%, while Royal Caribbean (RCL) rallied more than 80% over the same period. Trump's trades deals have, to some extent, helped the industry gain clarity. Airlines like United (UAL) and Delta (DAL) reinstated financial guidance, crediting a clear picture of signals out of Washington. Similarly, cruise operators noted a sharp improvement in bookings over the last several months. The rebound in cruise line stocks, Friday's market sell-off aside, came after April's market turmoil and subsequent recovery on the heels of President Trump's broad-based tariff pause. On Thursday, Norwegian Cruise Line shares jumped 9% after the company posted record second quarter revenue and shared bookings now ahead of historical levels. 'It's never a single thing that drives the change that we saw from a choppy April to a record May through July," Harry Sommer, president and CEO of Norwegian Cruise Line Holdings, told analysts during the earnings call. "But I'd say the primary driver was the improvement in the macroeconomic environment." He added that July was on its way to a record month for the company. Earlier this week, Royal Caribbean posted record adjusted earnings on strong demand, though the cruise operator's top line came in below Wall Street expectations. Management credited an acceleration in "close-in demand," or bookings with little lead-time, allowing operators to keep prices higher for longer. Strong performances from Royal Caribbean and Norwegian follow Carnival's record second quarter revenue of $6.3 billion in June. The industry's outperformance has been in the making for a while now. In recent years, cruise operators have invested in newer, more advanced ships; thematic voyages; and exclusive destination-led experiences to attract new customers. Those efforts appear to be working as cruises, which often work out cheaper than land-based vacations, have grown in popularity. The number of cruise passengers rose from 29.7 million in 2019, before the 2020 pandemic, to an estimated 37.7 million projected for 2025. The trend reflects passengers beyond baby boomers taking cruises as interest from first-time travelers rises. Royal Caribbean management noted this week that millennials and younger travelers now represent about half of its customer base. "Cruise is a good value proposition. So if people are thinking about taking a vacation, cruise is one of the cheaper forms of travel," Andrew Didora, senior equity research analyst at Bank of America, told Yahoo Finance. "I think [cruise lines] may be gaining some share within the vacation market." JPMorgan researchers estimate the cruise industry will expand its slice of the $1.9 trillion global vacation market from roughly 2% to 3.8% by 2028. Ines is a senior business reporter for Yahoo Finance. Follow her on X at @ines_ferre.